Regencell Bioscience Holdings Limited (RGC) Stock Analysis & Investment Frameworks
Regencell Bioscience Holdings Limited (RGC) stock analysis on Invetso. Review Regencell Bioscience Holdings Limited’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Regencell Bioscience Holdings Limited Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: HK
Regencell Bioscience Holdings Limited Key Financial Metrics
- Market Cap: $2.61B
- Revenue: $N/A
- ROE: -160.64%
- ROIC: -85.92%
- Dividend Yield: N/A
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.